Stockreport
Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note [Seeking Alpha]
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
The gain represented the biotech's largest daily one since July 9, when it closed up ~4.4%. The ESMO data showed that the median PFS in the Zynyz + chemo group was 9.3 months compared to 7.4 months in the chemo only arm. In a note, Guggenheim's Michael Schmidt said the Zynyz regimen would lead to a "robust uptake in a high unmet need population." He rates Incyte a buy with a $92 price target (~39% upside based on Sept. 16 close), just raised from $86. Recommended For You More Trending News Recommended For You More Trending News About INCY Stock Related Stocks Trending Analysis Trending News
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease [Yahoo! Finance][Yahoo! Finance]
- Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets [Yahoo! Finance][Yahoo! Finance]
- Incyte Co. (NASDAQ: INCY) had its "hold" rating re-affirmed by analysts at Truist Financial Co.. They now have a $74.00 price target on the stock, down previously from $83.00.[MarketBeat]
- Incyte Co. (NASDAQ: INCY) had its "market perform" rating re-affirmed by analysts at JMP Securities.[MarketBeat]
- Incyte Announces Promising New Data on Oncology Candidate at ESMO [Yahoo! Finance][Yahoo! Finance]
- More
INCY
SEC Filings
SEC Filings
- 9/16/24 - Form 4
- 9/16/24 - Form 4
- 9/13/24 - Form 144
- INCY's page on the SEC website
- More